Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.
Pacira BioSciences, Inc.’s planned acquisition of Flexion Therapeutics, Inc. and its osteoarthritis of the knee injectable Zilretta will allow the company to expand its offering of non-opioid drugs for treating pain while also enabling it to diversify its product offerings away from its flagship post-operative pain drug, Exparel (bupivacaine liposome injectable suspension).
Pacira and Flexion announced the all-cash deal on 11 October and expect it to close within the current quarter. Pacira...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
